ODN 1826

Research use only, not for human use.

ODN 1826 is a 20-mer DNA strand, a TLR9 agonist and an immunostimulant, with anti-tumor and cardioprotective effects, promoting apoptosis, and stimulating the production of NO and iNOS. ODN 1826 is a CpG DNA mimetic that can be used as an adjuvant for synthetic vaccines.

ODN 1826 (CpG 1826), a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. ODN 1826 promotes Apoptosis. ODN 1826 is an excellent immune stimulator with antitumor activity. ODN 1826 has protective effects on the heart. ODN 1826 sequence: 5’-tccatgacgttcctgacgtt-3’.

Western Blot Analysis Cell Line:RAW 264.7 Concentration:1 μg/mL Incubation Time:24 h Result:Increased the production of NO and iNOS.

Animal Model:Chronic vascular injury mouse models Dosage:18 nM CPG ODN Administration:s.c,three times a week for 7 weeks Result:Increased in aortic atherosclerotic plaque size compared to vehicle.Animal Model:Lewis Lung Cancer Murine Tumor ModelDosage:0.05 mg (1, 3, 5, 8, 11, 13 days) Administration:Intraperitoneal injection (i.p.)Result:Delayed tumor growth,decreased tumor weight and increased the apoptosis of tumor cells.

——

Immunology/Inflammation

TLR

TLR | NOS

——

——

202668-42-6

6364.1

——

>98% (HPLC)

In Vitro:?H2O : 50 mg/mL (7.86 mM; Ultrasonic)

——

——

(-20℃)

With Ice Pack

≥ 2 years